New Two-Pronged attack tested for rare, aggressive melanoma
NCT ID NCT05384496
Summary
This study is testing whether combining the drugs axitinib and nivolumab is a safe and effective first treatment for adults with advanced mucosal melanoma, a rare and aggressive cancer. The researchers believe blocking two different cancer growth pathways at once may work better than standard treatments. The trial will enroll 20 people who have not had any prior systemic therapy for their advanced disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCOSAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Westchester
RECRUITINGHarrison, New York, 10604, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.